Response Genetics, a Los Angeles-based company that develops molecular diagnostic tests for cancer and offers clinical trial specimen analysis services, named Thomas Bologna CEO.
Response Genetics names Bologna CEO
Bologna succeeds interim CEO Denise McNairn, who will continue to serve as the company's vice president, general counsel and secretary, according to a news release. He also was named chairman of the board, succeeding Kirk Calhoun, who was named to the newly created position of lead director.
Before joining Response Genetics, Bologna was president and CEO of Orchid Cellmark, which provides DNA identity testing. He has been president and CEO at a variety of other companies, as well, including Quorex Pharmaceuticals, which was sold to Pfizer; Ostex International, sold to Alere; Scriptgen Pharmaceuticals; and Gen-Probe. His age was unavailable at deadline.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.